EverPoint Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

EverPoint Asset Management’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-150,000	Closed	-$3.79M	–	588
2014 Q3	$3.79M	Buy	+150,000	New	+$3.95M	0.09%	289

Other funds holding PTLA

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

EverPoint Asset Management's PTLA Position: Q4 2014 in Review

EverPoint Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2014, closing a stake of 150,000 shares — an estimated $3.79M sold.

EverPoint Asset Management first reported a position in PTLA in Q3 2014 and held it in 1 quarter. The position peaked at $3.79M in Q3 2014. 133 funds tracked by Wall St. Rank hold PTLA as of Q4 2014.

EverPoint Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
EverPoint Asset Management sold 150,000 Portola Pharmaceuticals, Inc. shares in Q4 2014, an estimated $3.79M.
EverPoint Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
EverPoint Asset Management's Portola Pharmaceuticals, Inc. position peaked at $3.79M in Q3 2014.
133 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2014.

Based on EverPoint Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.